Editas Medicine, Inc. (NASDAQ:EDIT) 2024 Cantor Global Healthcare Conference September 17, 2024 1:20 PM ET Company Participants Gilmore O???Neill - CEO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Eric Schmidt Good afternoon, everyone. My name is Eric Schmidt, and I'm one of the, biotechnology analyst at Cantor Fitzgerald. So welcome to, the afternoon of day one of our Annual Healthcare Conference. With me today for this session is, Editas. We're delighted to have with us the company's Chie ...

Editas Medicine, Inc. (NASDAQ:EDIT) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM ET Company Participants Gilmore O’Neill - President and Chief Executive Officer Erick Lucera - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right. Thanks for joining us everybody. I'm Terence Flynn, the U.S. Biopharma analyst here at Morgan Stanley, very pleased to be hosting Editas. Today from the company ...

Company Strategy and Progress - The company has refocused its strategy on three pillars: driving reni-cel for sickle cell disease, rebuilding discovery for in vivo editing, and exploiting IP for non-dilutive financing [3] - Significant progress has been made in all three strategic pillars, with reni-cel showing highly differentiated efficacy and curative potential in sickle cell disease [4][5][6] - The company has dosed over 20 patients with reni-cel, completed adult cohort enrollment, and is ahead of schedule in adolescent cohort enrollment [6] - In vivo editing progress includes advancements in delivery systems and a focus on functional upregulation rather than knockdown, targeting hematopoietic stem cells and other tissues [7][8][9] Reni-cel Differentiation and Efficacy - Reni-cel has demonstrated curative potential with no vaso-occlusive events and correction of anemia in all treated patients, with hemoglobin levels normalized [5][6] - The therapy has shown durable efficacy, with patients maintaining normal hemoglobin levels for over five months [36] - Manufacturing and CMC processes have exceeded expectations, with significant progress in optimizing turnaround times [37][56] In Vivo Editing and Target Selection - The company is on track for in vivo proof of concept by the end of the year, focusing on functional upregulation and leveraging human genetics for target selection [14][23][24] - Statistical genetics and large biobank datasets are being used to identify natural variants and derisk target selection, similar to the approach used for reni-cel [24][25][26] - The company is targeting diseases with poor or nonexistent standard of care, focusing on orphan populations and biochemical markers for rapid readouts [10][11] IP Monetization and Partnerships - The company has licensed its Cas9 patent from Harvard MIT Broad, aiming to collect royalties similar to the Cabilly model, with potential deals structured based on company needs [15][16] - Approximately 100 programs across 10 companies have been identified as potential licensees, with discussions ongoing [63][64] - The collaboration with Bristol Myers has been extended, with six targets identified and two DCs achieved, highlighting the company's ability to enable oncology applications without direct focus [66][67][68] Commercial Strategy and Market Entry - The company plans to be a fast follower in the sickle cell market, leveraging the groundwork laid by Vertex and bluebird, with a focus on U.S. commercialization [45][46][49] - Pricing is expected to align with the $2-3 million range seen in the market, with a highly targeted sales force strategy focusing on approximately 75 U.S. treatment centers [50][54][55] - The company is open to ex-U.S. partnerships but will prioritize the U.S. market initially, with potential for lifecycle expansion into larger populations [46][49]

Editas Medicine, Inc. (EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter. Collaboration and other research and development (R&D) revenues, which comprise the company's top line, were $0.5 million in the second quarter, down from $2.9 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 ___________________ ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and Investor Relations Gilmore O’Neill - Chief Executive Officer Baisong Mei - Chief Medical Officer Erick Lucera - Chief Financial Officer Linda Burkly - Chief Scientific Officer Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Jack Allen - Baird Samantha Semenkow - Citi Eric Schmidt - Cantor Fitzgerald Terence Flynn ...

Editas Medicine (EDIT) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.56 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -18.84%. A quarter ago, it was expected that this genome editing company would post a loss of $0.63 per share when it actually produced a loss of $0.76, delivering a surprise of -20.63%. Over the last four quarters, the co ...

Editas Medicine Announces Second Quarter 2024 Results and Business Updates On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., August 7, 2024 – Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates ...

On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates. "We made significant progress in all three pillars of ou ...

This data readout follows the December 2023 press release, when the company last reported positive safety and efficacy data in 17 patients treated with reni-cel in the RUBY and EdiTHAL studies (11 and six patients, respectively). Editas stated that it has now dosed more than 20 SCD patients, completed adult cohort enrollment, and opened and enrolled patients in the adolescent cohort in the Ruby study, implicating significant progress. All patients in both studies demonstrated successful neutrophil and plate ...